| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9975366 | The Journal of Heart and Lung Transplantation | 2005 | 6 Pages |
Abstract
In this study sirolimus was found to be a valuable IS agent for the management of rejection, significant renal dysfunction and CNI side effects. These results support the need for prospective studies of the role of sirolimus in primary rejection prophylaxis, primary CAD prophylaxis and CAD regression. There also exists a need to establish an adverse event profile for this drug.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Natalia E. BSc, Stacey M. MA, PhD, Lori J. DPhil, Anne I. MD,